Your Article Summary
See Latest ArticlesRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Home PD et al. – Addition of rosiglitazone to glucose-lowering therapy in pts with type 2 diabetes is confirmed to increase risk of heart failure and of some fractures, mainly in women. Despite inconclusive data are about any possible effect on myocardial infarction, rosiglitazone does not increase risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs.
Methods- Study of cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea vs combination over 5—7 yr follow-up
- Assessment of comparative safety
- Multicentre, open-label trial of 4447 pts with type 2 diabetes on metformin or sulfonylurea monotherapy with mean hemoglobin A1c (HbA1c) of 7.9%
- Randomization to addition of rosiglitazone (n=2220) or combination of metformin and sulfonylurea (active control group, n=2227)
- Primary endpoint: cardiovascular hospitalization or cardiovascular death
- 321 pts in rosiglitazone group and 323 in active control group experienced primary outcome during mean 5.5-yr follow-up, meeting criterion of non-inferiority
- HR was 0.84 for cardiovascular death, 1.14 for myocardial infarction, and 0.72 for stroke
- Heart failure causing admission to hospital or death in 61 people in rosiglitazone group and 29 in active control group
- Upper and distal lower limb fracture rates increased mainly in women assigned to rosiglitazone
- Mean HbA1c lower in rosiglitazone vs control group at 5 yrs
Related Articles
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial)
Diabetes Care, 10/14/09
Relevance Score: 88%
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
Hepatology, 11/02/09
Relevance Score: 87%
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09
Relevance Score: 87%
Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone
Cardiovascular Drug Reviews, 11/17/09
Relevance Score: 85%
Stretch Reduces Nephrin Expression via an Angiotensin II-AT1-dependent Mechanism in Human Podocytes: Effect of Rosiglitazone
American Journal of Physiology: Renal Physiology, 11/17/09
Relevance Score: 85%
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Stem cell therapy in acute myocardial infarction: a review of clinical trials
Translational Research, The Journal of Laboratory and Clinical Medicine, 12/11/09
A novel explanation for the cause of atrial fibrillation seen in atherosclerotic coronary artery disease: “Downstream inflammation” hypothesis
Medical Hypotheses, 12/11/09
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study
Blood Pressure, 12/11/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus
Translational Research, The Journal of Laboratory and Clinical Medicine, 12/11/09
Emerging technologies in the delivery of erythropoietin for therapeutics
Medicinal Research Reviews, 12/11/09
Drug treatment of prehypertension: Not now, not ever
Blood Pressure, 12/11/09
Today in Vascular Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Pleiotropic effects of intravascular haemolysis on vascular homeostasis
British Journal of Haematology, 12/11/09
Relevance of the CX3CL1/fractalkine-CX3CR1 pathway in vasculitis and vasculopathy
Translational Research, The Journal of Laboratory and Clinical Medicine, 12/11/09
Stem cell therapy in acute myocardial infarction: a review of clinical trials
Translational Research, The Journal of Laboratory and Clinical Medicine, 12/11/09